NASDAQ:GPCR Structure Therapeutics (GPCR) Stock Price, News & Analysis $37.66 +0.79 (+2.13%) As of 12:51 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Structure Therapeutics Stock (NASDAQ:GPCR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Structure Therapeutics alerts:Sign Up Key Stats Today's Range$36.51▼$38.1550-Day Range$35.88▼$58.2252-Week Range$15.80▼$94.90Volume179,611 shsAverage Volume988,847 shsMarket Capitalization$2.67 billionP/E RatioN/ADividend YieldN/APrice Target$109.25Consensus RatingModerate Buy Company Overview Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders. The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development. These programs are directed at GPCR targets implicated in diseases such as nonalcoholic steatohepatitis (NASH), fibrosis and immune‐mediated inflammatory conditions. By applying structure‐guided optimization and high‐throughput screening, Structure Therapeutics aims to generate drug candidates with improved selectivity, potency and safety profiles compared with existing modalities. Founded in 2018, the company initially operated under the name GPCR Therapeutics before rebranding as Structure Therapeutics in 2023 to reflect its emphasis on structure‐based drug design. Headquartered in Boston, Massachusetts, Structure Therapeutics collaborates with academic centers, contract research organizations and strategic partners to advance its research and development programs. Its integrated approach combines in silico modeling, biophysical assays and in vivo validation to streamline candidate progression toward human trials. Led by a management team with extensive experience in drug discovery, translational research and clinical development, Structure Therapeutics aims to address areas of high unmet medical need. The company’s scientific leadership includes experts in GPCR biology, structural biology and pharmacology, positioning it to capitalize on breakthroughs in receptor structure elucidation and computational methods. Through its novel platform and focused pipeline, Structure Therapeutics seeks to bring first‐in‐class or best‐in‐class therapies to patients worldwide. AI Generated. May Contain Errors. Read More Structure Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreGPCR MarketRank™: Structure Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 269th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingStructure Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 3 strong buy ratings, 13 buy ratings, 1 hold rating, and 2 sell ratings.Upside PotentialStructure Therapeutics has a consensus price target of $109.25, representing about 189.4% upside from its current price of $37.75.Amount of Analyst CoverageStructure Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Structure Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Structure Therapeutics are expected to decrease in the coming year, from ($1.29) to ($1.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Structure Therapeutics is -43.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Structure Therapeutics is -43.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStructure Therapeutics has a P/B Ratio of 1.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Structure Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.93% of the float of Structure Therapeutics has been sold short.Short Interest Ratio / Days to CoverStructure Therapeutics has a short interest ratio ("days to cover") of 6.76.Change versus previous monthShort interest in Structure Therapeutics has recently decreased by 2.84%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldStructure Therapeutics does not currently pay a dividend.Dividend GrowthStructure Therapeutics does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.79 News SentimentStructure Therapeutics has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Structure Therapeutics this week, compared to 4 articles on an average week.Search Interest26 people have searched for GPCR on MarketBeat in the last 30 days. This is an increase of 189% compared to the previous 30 days.MarketBeat Follows5 people have added Structure Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Structure Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.60% of the stock of Structure Therapeutics is held by insiders.Percentage Held by Institutions91.78% of the stock of Structure Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Structure Therapeutics' insider trading history. Receive GPCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Structure Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GPCR Stock News HeadlinesThis Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 MillionMay 17, 2026 | fool.comStructure Therapeutics (NASDAQ:GPCR) Lowered to Sell Rating by Wall Street ZenMay 16, 2026 | americanbankingnews.comIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.May 21 at 1:00 AM | American Alternative (Ad)Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent HighlightsMay 7, 2026 | globenewswire.comWhy Structure Therapeutics (GPCR) Is Down 7.2% After Strong Oral GLP-1 Phase 2 Data And FDA PlansMay 3, 2026 | finance.yahoo.comHere is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look atMay 1, 2026 | finance.yahoo.comCanaccord Genuity initiates coverage of Structure Therapeutics Inc. - Depositary Receipt (GPCR) with buy recommendationApril 28, 2026 | msn.comStructure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific SessionsApril 27, 2026 | globenewswire.comSee More Headlines GPCR Stock Analysis - Frequently Asked Questions How have GPCR shares performed this year? Structure Therapeutics' stock was trading at $69.55 on January 1st, 2026. Since then, GPCR shares have decreased by 45.7% and is now trading at $37.7450. How were Structure Therapeutics' earnings last quarter? Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) released its earnings results on Thursday, May, 7th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.04. When did Structure Therapeutics IPO? Structure Therapeutics (GPCR) raised $150 million in an initial public offering (IPO) on Friday, February 3rd 2023. The company issued 10,740,000 shares at $13.00-$15.00 per share. Who are Structure Therapeutics' major shareholders? Structure Therapeutics' top institutional investors include Janus Henderson Group PLC (7.56%), Principal Financial Group Inc. (2.48%), Orbimed Advisors LLC (2.08%) and Siren L.L.C. (1.88%). How do I buy shares of Structure Therapeutics? Shares of GPCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Structure Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Structure Therapeutics investors own include Alamos Gold (AGI), Plug Power (PLUG), KALA BIO (KALA), Ovid Therapeutics (OVID), Comtech Telecommunications (CMTL), Fortress Biotech (FBIO) and Alto Ingredients (ALTO). Company Calendar Last Earnings5/07/2026Today5/21/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 As of 3 days ago, GPCR's financial health entered the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GPCR CIK1888886 Webwww.structuretx.com Phone628-229-9277FaxN/AEmployees136Year FoundedN/APrice Target and Rating Average Price Target for Structure Therapeutics$109.25 High Price Target$145.00 Low Price Target$65.00 Potential Upside/Downside+190.1%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage19 Analysts Profitability EPS (Trailing Twelve Months)($0.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$141.20 million Net MarginsN/A Pretax MarginN/A Return on Equity-24.91% Return on Assets-23.67% Debt Debt-to-Equity RatioN/A Current Ratio26.16 Quick Ratio26.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$20.43 per share Price / Book1.84Miscellaneous Outstanding Shares70,840,000Free Float66,875,000Market Cap$2.67 billion OptionableOptionable Beta-1.31 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:GPCR) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
